As an illustration, researchers constructed an organoid biobank from colorectal cancer patient tumor tissues, with these organoids retaining the genomic characteristics of the original tumors, including mutations in APC, TP53, and KRAS. High-throughput screening revealed that these patient-specific organoids could accurately predict responses to standard chemotherapy and targeted therapies. Here, KRAS is linked to colorectal cancer.